After a night’s sleep and a couple hundred angry comments and emails, I think I’ve figured a couple of things out about the Ryan Braun reaction and people’s overall feelings about MLB’s drug testing program. Mostly, though, I’m just dumbfounded at the cynicism and intellectual dishonesty of so many who wish to ignore the arbitrator’s ruling and cast Braun as a PED-using villain regardless.
For years, people argued for Major League Baseball to adopt a rigorous testing regime. Why? To end the speculation. To stop the “is he using or isn’t he” parlor games. Read every single column written about Jeff Bagwell’s Hall of Fame candidacy and you’ll find some variation of “but for so long there was no testing, so we just can’t know, and that uncertainty is horrible …” sentiment.
Now we have a testing program. And it’s amazing to me just how quickly the end product of that testing program — no suspension for Ryan Braun — is diminished or outright dismissed when results aren’t what people wanted.
I’m talking about those who don’t care that the procedures weren’t followed and say that they still don’t think Braun is clean, his name not cleared. Sure, you’re allowed to think that if you want, but just understand that if you do — if “we still don’t think he’s clean” or “questions still remain” holds — then there is no purpose whatsoever to have a testing program in the first place. Because even with one in place, people will just assume what they want to assume regardless of the end product, and that’s no different than where we were in 1998.
The reason? Because no scientific protocol has legitimacy if only some parts of it are adhered to and others aren’t. When you go with testing, you go with everything. You can’t say that the preliminary test results matter and the chain of custody protocols don’t. It’s all of a piece. It’s the entire process that lends drug testing its legitimacy, not just part of it.
But hey, if you still want to crap on Braun — if you still want to say “but his testosterone levels were high, so he’s suspect” or “MLB has egg on its face because the testing failed” — fine. Do so. It’s a free country. But if you do so, admit that you do it because you simply don’t like the results here. And spare me any whining about the past, and about how Major League Baseball was so lax in testing for so many years before now. Because as is evidenced by your Ryan Braun reactions, you wouldn’t have cared regardless.
New Mariners general manager Jerry Dipoto has kept pretty busy in his short time on the job and Bob Dutton of the Tacoma News Tribune reports that free agent outfielder Nori Aoki could be his next target. The club recently pursued a trade for Marlins outfielder Marcell Ozuna, but the asking price has them looking at alternatives.
Aoki, who turns 34 in January, has hit .287 with a .353 on-base percentage over four seasons since coming over from Japan. He was having a fine season with the Giants this year prior to being shut down in September with lingering concussion symptoms.
The Giants decided against picking up Aoki’s $5.5 million club option for 2016 earlier this month, but he should still do pretty well for himself this winter assuming he’s feeling good.
It was reported Sunday that free agent right-hander Johnny Cueto had turned down a six-year, $120 million contract from the Diamondbacks. He’s hoping to land a bigger deal this winter and ESPN’s Jerry Crasnick has heard some chatter about what he’s looking for.
Jordan Zimmermann finalized a five-year, $110 million contract with the Tigers today, which works out to $22 million per season. Arizona’s offer to Cueto checked in at $20 million per season. A six-year offer to Cueto at the same AAV (average annual value) as Zimmermann would put him at $132 million, which is still a little shy of the figure stated by Crasnick. Of course, Cueto owns a 2.71 ERA (145 ERA+) over the last five seasons compared to a 3.14 ERA (123 ERA+) by Zimmermann during that same timespan, so there’s a case to be made that he should get more. Still, he’s the clear No. 3 starter on the market behind David Price and Zack Greinke.
CBS Sports’ Jon Heyman reports that the Dodgers, Giants, Red Sox, and Cubs are among the other teams who have interest in Cueto. One variable in his favor is that he is not attached to draft pick compensation, as he was traded from the Reds to the Royals during the 2015 season.
The rebuilding Braves have already been active on the trade market and they might not be done, as CBS Sports’ Jon Heyman reports that right-hander Shelby Miller has been a very popular name. In fact, around 20 teams have checked in.
Nothing is considered close and the Braves have set a very high asking price, mostly centered around offense. They asked for right-hander Luis Severino in talks with the Yankees and would expect outfielder Marcell Ozuna among other pieces from the Marlins. The Diamondbacks and Giants are among the other interested clubs.
Miller is under team control through 2018, so there’s not necessarily a sense of urgency to move him, but anything is possible with the way the Braves are doing things right now. The 25-year-old is coming off a year where he went 6-17, but that was about really rotten luck more than anything else, as he had a fine 3.02 ERA and 171/73 K/BB ratio over 205 1/3 innings. The Braves gave him the worst run support of any starter in the majors.
Jenrry Mejia appeared in just seven games this past season due to a pair of suspensions for performance-enhancing drugs, but Adam Rubin of ESPN New York reports that the Mets are expected to tender him a contract for 2016.
While the Mets were vocal about their disappointment in Mejia’s actions, it makes sense to keep him around as an option. Had he played a full season in 2015, he would have earned $2.595 million. He’s arbitration-eligible for the second time this winter and figures to receive a contract similar to his 2015 figure, but he’ll only be paid for the games he plays. He still has 100 games to serve on his second PED suspension, which means that he’ll only be paid for 62 games in 2016. This likely puts his salary closer to $1 million, which is a small price to pay for someone who could prove useful during the second half and beyond. He also won’t count toward the team’s 40-man roster until he’s active.
Mejia, who turned 26 in October, owns a 3.68 ERA in the majors and saved 28 games for the Mets in 2014. He’s currently pitching as a starter in the Dominican Winter League.